Clinical-stage oncology company Lantern Pharma Inc (NASDAQ:LTRN) on Wednesday announced a complete metabolic response in a Phase 1 trial of LP-284, achieved by a patient with aggressive, treatment-resistant diffuse large B-cell lymphoma after only two cycles of therapy.

This marks the first complete response for LP-284 and demonstrates promising clinical activity in a high-risk, refractory setting.

The 41-year-old patient had failed three prior regimens -- R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and glofitamab, a CD3xCD20 bispecific antibody -- before enrolling in April 2025. LP-284, administered over a 28-day cycle, led to non-avid lesions, indicating complete disease remission.

LP-284 was developed using Lantern's proprietary RADR artificial intelligence platform, which systematically analyses molecular vulnerabilities to optimise drug candidates for genetically defined cancer populations. The platform enabled Lantern to bring LP-284 into the clinic in under three years at a cost of approximately USD3m.

The result supports LP-284's synthetic lethal mechanism and potential as a differentiated treatment in relapsed or refractory B-cell malignancies, particularly where other advanced therapies have failed. The compound has received multiple Orphan Drug Designations from the US Food and Drug Administration, including for mantle cell lymphoma and high-grade B-cell lymphomas.

Lantern continues to enrol patients in its ongoing Phase 1 study, which is focused on aggressive non-Hodgkin lymphoma subtypes. This milestone strengthens the company's strategic position in haematologic oncology and highlights opportunities for future partnerships and global expansion.